Proxalutamide (GT0918) is an orally active potent androgen receptor (AR) antagonist. Proxalutamide (GT0918) can be used in the study for prostate cancer and COVID-19.
Form:Solid
IC50& Target:Androgen Receptor.
In Vitro:Proxalutamide (GT0918) down-regulates AR protein level in prostate cancer cells. Proxalutamide can overcome the resistance of prostatic cancer cells by downregulating the expression of AR genes. Proxalutamide (GT0918, 0-200 μM) dose-dependently inhibits cell viability in LNCaP and 22RV1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay. Cell Line: Four human PCa cell lines, LNCaP, 22RV1, PC3 and DU145. Concentration: 1, 2, 5, 10, 20, 50, 100, and 200 μM. Incubation Time: Up to 72 h. Result: Preferentially affected AR-positive PCa cells (IC 50 values from 6.90 to 32.07 μM) over AR-negative cells (IC 50 > 200 μM).
In Vivo:The elimination half-life (t 1/2 ) of proxalutamide in rats is approximately 2 h regardless of whether it is administered by the intragastric or the intravenous route. The maximum plasma concentration of proxalutamide (Cmax) could reach 2 μg/mL or higher, and the oral absolute bioavailability (F) was approximately 80% [4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rats [4] . Dosage: 20 mg/kg (Pharmacokinetic Analysis). Administration: Intragastrically. Result: T 1/2 = 2 h and F% = 80%